GlassScriptPhysician profile
Brett A Siegle
NPI 1689055667
$1,157.82
in general payments reported to CMS, 2019-2025
24 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.80 · 2020: $20.59 · 2021: $149 · 2022: $221 · 2023: $136 · 2024: $288 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $210.27 | 2019-2024 | |
| Novo Nordisk INC | $154.67 | 2021-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.43 | 2025 | Caplyta |
| Lilly USA, LLC | $79.62 | 2021-2024 | Mounjaro |
| Mylan Specialty L.P. | $69.77 | 2022-2023 | Yupelri |
| Pfizer INC. | $61.90 | 2025 | |
| Exact Sciences Corporation | $60.47 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.19 | 2022-2024 | Jardiance |
| Boston Scientific Corporation | $44.36 | 2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $42.45 | 2023-2024 | Farxiga |
| Dexcom, INC. | $38.49 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $32.88 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $32.83 | 2019 | |
| Neurocrine Biosciences, INC. | $22.83 | 2025 | |
| Insulet Corporation | $21.99 | 2025 | Omnipod |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.59 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.72 | 2023 | Keveyis |
| Tactile Systems Technology INC | $19.06 | 2025 | Nimbl, Flexitouch Plus |
| Edwards Lifesciences Corporation | $18.93 | 2023 | Sapien 3 Ultra Resilia |
| Amgen INC. | $14.41 | 2025 | Evenity |
| Astellas Pharma US INC | $12.90 | 2019 | |
| Electromed, INC. | $12.80 | 2021 | |
| Siemens Medical Solutions USA, INC. | $12.49 | 2021 | |
| Abbott Laboratories | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Siegle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.